Pasterz R B, Buzdar A U, Hortobagyi G N, Blumenschein G R
Cancer. 1985 Nov 15;56(10):2381-4. doi: 10.1002/1097-0142(19851115)56:10<2381::aid-cncr2820561006>3.0.co;2-2.
Forty-three patients with evaluable metastatic breast cancer refractory to hormonal agents and extensive combination chemotherapy including doxorubicin were treated with mitomycin, 20 mg/m2 intravenously every 6 weeks. There were five partial responses (12%) and three minor responses (7%), with a mean time to progression of 5 months and 3.5 months, respectively. Thrombocytopenia was the major dose-limiting toxicity, and myelosuppression was cumulative. Cardiac dysfunction was observed in 12% of patients. Mitomycin had some antitumor activity in this group of metastatic breast cancer patients refractory to extensive combination chemotherapy including doxorubicin.
43例对激素药物及包括阿霉素在内的多种联合化疗耐药、可评估的转移性乳腺癌患者接受了丝裂霉素治疗，剂量为20mg/m²，每6周静脉注射1次。有5例部分缓解（12%），3例轻度缓解（7%），平均进展时间分别为5个月和3.5个月。血小板减少是主要的剂量限制性毒性，骨髓抑制具有累积性。12%的患者观察到心脏功能障碍。在这组对包括阿霉素在内的多种联合化疗耐药的转移性乳腺癌患者中，丝裂霉素具有一定的抗肿瘤活性。
